Venture Life (17V) AI Stock Analysis

Venture Life

(Frankfurt:17V)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved ProfitabilityThe return to positive EBIT and materially higher net income indicates stronger underlying earnings power. If maintained, improved profitability can support reinvestment, strengthen resilience, and provide greater flexibility to expand the branded healthcare portfolio.

Negative Factors

Negative Recent Cash FlowThe reversal to negative operating and free cash flow weakens confidence that reported earnings are converting consistently into cash. Persistent working-capital demands or one-off uses of cash could restrict investment capacity and reduce financial flexibility.

Venture Life (17V) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 80.73M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 15.6
Beta (1Y): 0.13
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 63
Sector: Consumer Defensive
Sector Strength: 62
Industry: Medical - Pharmaceuticals

Venture Life Business Overview & Revenue Model

Company Description

Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetic...

Venture Life Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:17V against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:HLN	63Neutral	GBP 28.09B	17.61	9.89%	2.29%	1.21%	8.33%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
GB:PXS	49Neutral	GBP 18.77M	-80.00	-44.68%	―	-2.14%	0.00%
GB:AGY	42Neutral	GBP 253.30M	-4.04	409.00%	―	2.94%	-32.00%
GB:STX	42Neutral	GBP 60.69M	-7.72	64.57%	―	36.19%	60.75%

* Consumer Defensive Sector Average

Performance Comparison

DE:17V and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:17V	Venture Life	0.79	0.20	32.77%
GB:AGY	Allergy Therapeutics	4.00	-4.45	-52.66%
GB:PXS	Provexis plc	0.80	0.22	36.75%
GB:STX	Shield Therapeutics	5.65	-1.25	-18.12%
GB:HLN	Haleon PLC	319.40	-31.39	-8.95%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Venture Life AI Stock Analysis